Thiotepa Abcur (Thiotepa)
Alkylating agent for conditioning before stem cell transplantation
Thiotepa Abcur is a potent alkylating chemotherapy agent containing the active substance thiotepa. It is used exclusively in a hospital setting as part of conditioning regimens before hematopoietic stem cell transplantation (HSCT). Thiotepa works by destroying bone marrow cells, enabling the body to accept transplanted stem cells that will produce healthy new blood cells. It is approved for use in both adults and children.
Quick Facts
Key Takeaways
- Thiotepa Abcur is an alkylating agent used exclusively as conditioning treatment before hematopoietic stem cell transplantation (HSCT) in both adults and children.
- It is administered as an intravenous infusion over 2–4 hours, typically every 12 or 24 hours for up to 5 consecutive days in a hospital setting.
- The most serious side effects include severe myelosuppression, life-threatening infections, hepatic veno-occlusive disease, and graft-versus-host disease.
- Thiotepa can impair fertility in both men and women – sperm banking and fertility counseling should be discussed before treatment.
- This medication must never be used during pregnancy or breastfeeding, and live vaccines are contraindicated during treatment.
What Is Thiotepa Abcur and What Is It Used For?
Thiotepa Abcur belongs to a group of chemotherapy medicines known as alkylating agents. These drugs work by forming covalent bonds with DNA molecules inside cells, creating cross-links between DNA strands that prevent the cell from dividing and ultimately lead to cell death. In the context of stem cell transplantation, this cytotoxic effect is deliberately used to ablate (destroy) the patient's existing bone marrow, clearing space for the transplanted donor or autologous stem cells.
The primary clinical use of Thiotepa Abcur is as a conditioning agent prior to hematopoietic stem cell transplantation (HSCT). Conditioning is a critical preparatory phase during which high-dose chemotherapy – often combined with other agents such as busulfan, cyclophosphamide, or melphalan – is administered to achieve two key goals: myeloablation (destruction of the existing bone marrow) and immunosuppression (suppression of the immune system to prevent rejection of transplanted cells).
Thiotepa has a unique pharmacological advantage in its ability to cross the blood-brain barrier, making it particularly valuable in conditioning regimens for patients with central nervous system (CNS) involvement, including primary CNS lymphoma and CNS tumors in both adults and children. This property distinguishes it from many other alkylating agents used in transplant conditioning.
Approved Indications
Thiotepa Abcur is approved for use in conditioning regimens before both autologous HSCT (using the patient's own stem cells) and allogeneic HSCT (using donor stem cells) across a broad range of conditions:
- Hematological malignancies: Lymphoma, multiple myeloma, leukemia (acute and chronic), and CNS lymphoma
- Solid tumors: Breast cancer, ovarian cancer, CNS tumors, and germ cell tumors
- Non-malignant conditions (pediatric): Thalassemia, sickle cell anemia, refractory cytopenia, and certain genetic diseases
Thiotepa Abcur is suitable for use in adults, adolescents, and children. The specific dosing, scheduling, and combination with other chemotherapy agents depends on the type of transplant, the underlying disease, and whether the patient is an adult or a child. All treatment is conducted under the supervision of experienced transplant physicians in specialized healthcare centers.
What Should You Know Before Receiving Thiotepa Abcur?
Contraindications
Thiotepa Abcur should not be administered in the following situations:
- Hypersensitivity: Known allergy to thiotepa or any of the excipients in the formulation
- Pregnancy: Thiotepa is teratogenic and embryotoxic. Women who are pregnant or suspected of being pregnant must not receive this medication
- Breastfeeding: It is unknown whether thiotepa is excreted in human breast milk. Breastfeeding must be discontinued during treatment as a precaution
- Live vaccines: Vaccination with live viral or bacterial vaccines (including yellow fever vaccine) is contraindicated due to the severe immunosuppression caused by thiotepa
Warnings and Precautions
Before initiating treatment with Thiotepa Abcur, your healthcare team will carefully evaluate your overall health status. Inform your physician if you have any of the following conditions, as they may affect your treatment:
- Liver or kidney problems: Impaired hepatic or renal function may affect how the drug is metabolized and excreted, potentially increasing toxicity
- Heart or lung conditions: Pre-existing cardiac or pulmonary disease may increase the risk of treatment-related complications
- Seizure disorders: Patients with epilepsy or a history of seizures require careful monitoring. Those taking phenytoin or fosphenytoin should inform their doctor, as drug interactions may occur
Because Thiotepa Abcur destroys bone marrow cells responsible for producing blood cells, severe myelosuppression is an expected and intended effect. Your medical team will perform regular blood tests throughout treatment to monitor blood cell counts and initiate supportive care including infection prevention, blood transfusions, and growth factor support as needed.
Like many alkylating agents, thiotepa may increase the risk of developing a secondary cancer in the future. This is a known class effect of cytotoxic chemotherapy. Your oncologist will discuss this risk with you as part of the informed consent process, weighing it against the significant survival benefit provided by stem cell transplantation for your underlying condition.
Pregnancy and Breastfeeding
Thiotepa Abcur poses significant risks to reproductive health and fetal development. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, you must inform your healthcare team before receiving this medication.
- Pregnancy: Thiotepa is contraindicated during pregnancy. Both men and women must use effective contraception throughout treatment
- Male fertility: Men should seek advice about sperm banking before treatment begins. Men should not father children during treatment and for one year after the end of treatment
- Female fertility: Thiotepa may impair female fertility. Discuss fertility preservation options (such as egg or embryo freezing) with your medical team before treatment
- Breastfeeding: Women must not breastfeed during treatment with Thiotepa Abcur
Driving and Operating Machinery
Certain side effects of Thiotepa Abcur – including dizziness, headache, and blurred vision – may impair your ability to drive or operate machinery safely. If you experience any of these symptoms, refrain from driving or using machinery until they resolve. Discuss any concerns with your healthcare provider.
How Does Thiotepa Abcur Interact with Other Drugs?
Thiotepa is metabolized primarily by the cytochrome P450 enzyme system, particularly CYP2B6 and CYP3A4. Any medication that inhibits or induces these enzymes can potentially alter the plasma concentration of thiotepa and its active metabolite TEPA, which may affect both efficacy and toxicity. Because conditioning regimens for stem cell transplantation typically involve multiple chemotherapy agents, the potential for cumulative toxicity and drug interactions is an important clinical consideration.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Live vaccines (e.g., yellow fever, BCG, MMR) | Risk of severe or fatal infection from live organism | Contraindicated – do not administer |
| Phenytoin / Fosphenytoin | Altered seizure control; potential enzyme induction affecting thiotepa levels | Close monitoring required; dose adjustment may be needed |
| Other alkylating agents (cyclophosphamide, busulfan, melphalan) | Additive myelosuppression and organ toxicity | Expected in conditioning regimens; doses carefully calculated |
| CYP2B6 / CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) | Increased thiotepa plasma concentration; reduced conversion to TEPA | May increase toxicity; inform your medical team |
Minor Interactions
While the interactions listed above are the most clinically significant, patients should always provide a complete medication history to their healthcare team. This includes prescription medications, over-the-counter drugs, herbal supplements, and vitamins. Because thiotepa is exclusively administered in a hospital setting under close medical supervision, the transplant team will carefully review all concomitant medications and make necessary adjustments to minimize interaction risks.
It is also important to note that after stem cell transplantation, patients typically receive multiple supportive medications including anti-infective prophylaxis (antibacterial, antifungal, and antiviral agents), immunosuppressants (to prevent graft-versus-host disease), and growth factors. All of these are managed by the transplant team with careful attention to potential interactions.
What Is the Correct Dosage of Thiotepa Abcur?
Thiotepa Abcur dosing is highly specialized and varies considerably depending on multiple factors including the patient's age, body surface area or weight, the type of HSCT being performed, and the underlying condition being treated. The drug is always administered in combination with other conditioning agents as part of a carefully planned protocol. Doses below represent recommended ranges from international guidelines and approved labeling.
Adult Dosing
Autologous HSCT – Hematological Diseases
Lymphoma
125–300 mg/m²/day (3.38–8.10 mg/kg/day) as a single daily infusion for 2–4 consecutive days. Maximum cumulative dose: 900 mg/m² (24.32 mg/kg).
CNS Lymphoma
185 mg/m²/day (5 mg/kg/day) as a single daily infusion for 2 consecutive days. Maximum cumulative dose: 370 mg/m² (10 mg/kg).
Multiple Myeloma
150–250 mg/m²/day (4.05–6.76 mg/kg/day) as a single daily infusion for 3 consecutive days. Maximum cumulative dose: 750 mg/m² (20.27 mg/kg).
Autologous HSCT – Solid Tumors
Breast Cancer
120–250 mg/m²/day (3.24–6.76 mg/kg/day) as a single daily infusion for 3–5 consecutive days. Maximum cumulative dose: 800 mg/m² (21.62 mg/kg).
CNS Tumors
125–250 mg/m²/day (3.38–6.76 mg/kg/day) in one or two daily infusions for 3–4 consecutive days. Maximum cumulative dose: 750 mg/m² (20.27 mg/kg).
Ovarian Cancer
250 mg/m²/day (6.76 mg/kg/day) as a single infusion for 2 consecutive days. Maximum cumulative dose: 500 mg/m² (13.51 mg/kg).
Germ Cell Tumors
150–250 mg/m²/day (4.05–6.76 mg/kg/day) as a single daily infusion for 3 consecutive days. Maximum cumulative dose: 750 mg/m² (20.27 mg/kg).
Allogeneic HSCT – Hematological Diseases
Lymphoma
370 mg/m²/day (10 mg/kg/day) divided into two daily infusions. Maximum cumulative dose: 370 mg/m² (10 mg/kg).
Leukemia
185–481 mg/m²/day (5–13 mg/kg/day) in one or two daily infusions for 1–2 consecutive days. Maximum cumulative dose: 555 mg/m² (15 mg/kg).
Multiple Myeloma
185 mg/m²/day (5 mg/kg/day) as a single daily infusion. Maximum cumulative dose: 185 mg/m² (5 mg/kg).
Thalassemia
370 mg/m²/day (10 mg/kg/day) divided into two daily infusions. Maximum cumulative dose: 370 mg/m² (10 mg/kg).
Pediatric Dosing
Pediatric dosing is weight-based and depends on the type of transplant and underlying disease. The following are key dosage ranges:
Autologous HSCT
Solid Tumors (including CNS tumors)
150–350 mg/m²/day (6–14 mg/kg/day) as a single daily infusion for 2–3 consecutive days. Maximum cumulative dose: 1,050 mg/m² (42 mg/kg).
Allogeneic HSCT
Leukemia
250 mg/m²/day (10 mg/kg/day) divided into two daily infusions. Maximum cumulative dose: 250 mg/m² (10 mg/kg).
Thalassemia
200–250 mg/m²/day (8–10 mg/kg/day) divided into two daily infusions. Maximum cumulative dose: 250 mg/m² (10 mg/kg).
Sickle Cell Anemia
250 mg/m²/day (10 mg/kg/day) divided into two daily infusions. Maximum cumulative dose: 250 mg/m² (10 mg/kg).
Refractory Cytopenia
125 mg/m²/day (5 mg/kg/day) as a single daily infusion for 3 consecutive days. Maximum cumulative dose: 375 mg/m² (15 mg/kg).
Genetic Diseases
125 mg/m²/day (5 mg/kg/day) as a single daily infusion for 2 consecutive days. Maximum cumulative dose: 250 mg/m² (10 mg/kg).
How Thiotepa Abcur Is Administered
Thiotepa Abcur is supplied as a white lyophilized (freeze-dried) powder in glass vials. Before administration, the powder must be reconstituted with sterile water for injection (1.5 mL for the 15 mg vial; 10 mL for the 100 mg vial) to produce a concentrate of 10 mg/mL. This concentrate is then further diluted in 500 mL of 0.9% sodium chloride solution (or 1,000 mL if the dose exceeds 500 mg) to achieve a final concentration between 0.5 and 1 mg/mL.
The diluted solution is administered as an intravenous infusion over 2–4 hours at room temperature using an infusion set equipped with a 0.2 μm in-line filter. The indwelling catheter is flushed with approximately 5 mL of 0.9% sodium chloride solution before and after each infusion. Each infusion is given every 12 or 24 hours, and the course of treatment may last up to 5 days depending on the protocol.
Overdose
There is no specific antidote for thiotepa overdose. In the event of overdose, the primary concern is profound myelosuppression with potential life-threatening pancytopenia, as well as severe organ toxicity. Treatment would be supportive, focusing on blood product transfusions, infection management, and organ support. Any suspected overdose should be managed by the experienced transplant team in an intensive care setting.
What Are the Side Effects of Thiotepa Abcur?
Like all chemotherapy medicines, Thiotepa Abcur can cause side effects, though not everyone experiences all of them. Many side effects are expected consequences of the drug's mechanism of action and the transplantation process itself. Your medical team will closely monitor you throughout treatment and provide supportive care to manage these effects. The side effects are categorized below by frequency according to international reporting standards.
Very Common
- Increased susceptibility to infections and sepsis (blood poisoning)
- Decreased white blood cells, platelets, and red blood cells (anemia)
- Graft-versus-host disease (transplanted cells attack the body)
- Dizziness, headache, blurred vision, seizures
- Tingling, numbness, or pins-and-needles sensation (paresthesia)
- Cardiac arrest, arrhythmia (abnormal heart rhythm)
- Nausea, vomiting, diarrhea, loss of appetite
- Mucositis (inflammation of mouth and digestive tract lining)
- Skin rash, itching, skin peeling, redness, hair loss
- Back pain, abdominal pain, muscle and joint pain
- Lung tissue inflammation, enlarged liver
- Hepatic veno-occlusive disease (blockage of liver veins), jaundice
- Elevated liver, kidney, and digestive enzymes
- High blood sugar, electrolyte imbalances, weight gain
- Fever, general weakness, chills, bleeding, nosebleeds
- Edema (generalized swelling), eye infection (conjunctivitis)
- Hearing impairment, high blood pressure, lymphatic obstruction
- Decreased sperm count, vaginal bleeding, absent menstruation
- Memory loss, confusion, delayed growth (in children)
- Insufficient thyroid hormone or testosterone production
- Pituitary gland insufficiency, bladder dysfunction
Common
- Anxiety, confusion, brain hemorrhage
- Intracranial aneurysm (abnormal bulging of a brain artery)
- Elevated creatinine levels, allergic reactions
- Blood vessel blockage (embolism), heart rhythm disturbances
- Heart failure, cardiovascular failure, oxygen deficiency
- Pulmonary edema (fluid in lungs), lung bleeding, respiratory arrest
- Blood in urine, bladder inflammation, reduced urine output
- Cataract (lens clouding), liver failure
- Cough, constipation, bowel obstruction, stomach perforation
- Bruising due to low platelets, menopausal symptoms
- Secondary cancers, male and female infertility
Uncommon
- Skin inflammation and peeling (erythrodermic psoriasis)
- Delirium, nervousness, hallucinations, agitation
- Gastrointestinal ulcers
- Myocarditis (inflammation of heart muscle)
- Cardiomyopathy (disease of heart muscle)
Frequency Not Known
- Pulmonary arterial hypertension (elevated blood pressure in lung arteries)
- Severe skin damage (extensive lesions, large blisters) – potentially life-threatening
- Leukoencephalopathy (damage to white brain matter) – potentially life-threatening
Contact your healthcare team immediately if you develop signs of infection (fever, chills, sore throat), unusual bleeding or bruising, severe abdominal pain, difficulty breathing, sudden severe headache, yellowing of skin or eyes, or any other new or worsening symptoms during or after treatment.
It is important to remember that many of these side effects are expected as part of the conditioning and transplantation process. Your transplant team has extensive experience in managing these complications and will provide comprehensive supportive care throughout your treatment journey. Not all patients experience all listed side effects, and the severity and duration vary between individuals.
How Should Thiotepa Abcur Be Stored?
Proper storage of Thiotepa Abcur is essential to maintain the drug's stability and ensure patient safety. As a hospital-administered medication, storage is managed by pharmacy and nursing staff according to strict protocols. The following storage requirements apply:
- Unopened vials: Store and transport refrigerated at 2–8°C (36–46°F). Do not freeze
- After reconstitution: The reconstituted concentrate (10 mg/mL) is stable for 8 hours when stored at 2–8°C
- After dilution: The diluted infusion solution is stable for 24 hours when stored at 2–8°C, or 4 hours at room temperature (20–25°C)
- From a microbiological standpoint: The product should be used immediately after preparation
- Do not use after the expiration date printed on the carton and vial label
- Keep out of sight and reach of children
Unused medicine and waste material should be disposed of in accordance with local regulations for cytotoxic waste. Healthcare professionals handling Thiotepa Abcur should follow standard precautions for cytotoxic agents, including the use of protective gloves and preparation under a laminar airflow safety hood using aseptic technique. In case of accidental skin contact, the area should be washed immediately and thoroughly with soap and water. Mucous membranes should be flushed with copious amounts of water.
What Does Thiotepa Abcur Contain?
Thiotepa Abcur has an unusually simple formulation. The product contains only the active substance thiotepa with no additional excipients (inactive ingredients). This makes it one of the simplest pharmaceutical formulations available.
Available Presentations
| Presentation | Content | After Reconstitution | Packaging |
|---|---|---|---|
| 15 mg vial | 15 mg thiotepa (white lyophilized powder) | 10 mg/mL (reconstituted with 1.5 mL sterile water) | 1 glass vial per carton |
| 100 mg vial | 100 mg thiotepa (white lyophilized powder) | 10 mg/mL (reconstituted with 10 mL sterile water) | 1 glass vial per carton |
The reconstituted solution may occasionally appear slightly opalescent or contain small, fine white flakes. This is due to inherent polymerization of the thiotepa molecule and does not indicate degradation. Such solutions may still be used for further dilution in the infusion bag. However, solutions that contain visible particles after further dilution should not be administered.
All reconstituted and diluted solutions must be inspected visually before administration. The infusion must be delivered through an infusion set equipped with a 0.2 μm in-line filter, which does not affect the drug's potency. Thiotepa Abcur is intended for single use only – any unused portion must be discarded according to local protocols for cytotoxic waste disposal.
Frequently Asked Questions About Thiotepa Abcur
Thiotepa Abcur is used exclusively as a conditioning treatment before hematopoietic stem cell transplantation (HSCT). It works by destroying bone marrow cells, making it possible for transplanted stem cells to engraft and produce new healthy blood cells. It is used in both autologous (patient's own cells) and allogeneic (donor cells) transplants for hematological malignancies (lymphoma, leukemia, multiple myeloma), solid tumors (breast, ovarian, CNS tumors), and non-malignant conditions in children (thalassemia, sickle cell anemia, genetic diseases).
Thiotepa Abcur is given as an intravenous infusion (IV drip) over 2 to 4 hours by qualified healthcare professionals in a hospital transplant unit. The powder is first reconstituted with sterile water and then further diluted in sodium chloride solution. Infusions are given every 12 or 24 hours for up to 5 consecutive days, depending on the treatment protocol and underlying condition.
The most serious side effects include severe myelosuppression (drastically reduced blood cell counts), life-threatening infections including sepsis, hepatic veno-occlusive disease (blockage of liver veins), graft-versus-host disease (in allogeneic transplants), cardiac arrest and arrhythmias, respiratory complications, and secondary cancers. Regular blood monitoring and comprehensive supportive care are essential during and after treatment.
Yes, Thiotepa Abcur is approved for use in children and adolescents. Pediatric indications include solid tumors (particularly CNS tumors), leukemia, thalassemia, sickle cell anemia, refractory cytopenia, and certain genetic diseases. Dosing is based on body surface area or weight and is adjusted according to the specific condition and type of transplant. Pediatric treatment is conducted by specialized pediatric transplant teams.
Yes, thiotepa can impair fertility in both men and women. Male patients should consider sperm banking before treatment begins and should not father children during treatment or for one year after treatment ends. Effective contraception is mandatory during treatment. Female patients should discuss fertility preservation options with their medical team. Women must not breastfeed during treatment. Long-term effects on endocrine function, including thyroid and gonadal function, require ongoing monitoring after transplantation.
Live vaccines are strictly contraindicated during and after treatment with Thiotepa Abcur due to the severe immunosuppression it causes. This includes vaccines for yellow fever, measles-mumps-rubella (MMR), varicella, and BCG. After stem cell transplantation, patients typically undergo a revaccination schedule starting several months post-transplant, once the immune system has recovered sufficiently. Your transplant team will advise you on the appropriate timing for vaccinations.
References and Medical Sources
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Thiotepa – Summary of Product Characteristics (SmPC). Accessed 2026.
- European Society for Blood and Marrow Transplantation (EBMT). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies, 7th Edition, 2019.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List, 2023.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Hematopoietic Cell Transplantation, 2025.
- Holtick U, et al. “Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.” Bone Marrow Transplantation. 2019;54(7):932–940.
- Chabannon C, et al. “Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies.” Science Translational Medicine. 2018;10(436):eaap9630.
- Bernaudin F, et al. “Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.” Blood. 2007;110(7):2749–2756.
- British National Formulary (BNF). Thiotepa monograph. National Institute for Health and Care Excellence (NICE). Accessed 2026.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in oncology, hematology, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to guidelines from the EMA, WHO, EBMT, and NCCN.
iMedic Medical Editorial Team – specialists in oncology and clinical pharmacology with expertise in hematopoietic stem cell transplantation.
iMedic Medical Review Board – independent panel ensuring accuracy, completeness, and adherence to current international evidence-based guidelines.
Published: | Last reviewed: | Evidence Level: 1A